🇺🇸 FDA
Pipeline program

Lotilaner ophthalmic solution, 0.25%

TRS-023

Approved small_molecule completed

Quick answer

Lotilaner ophthalmic solution, 0.25% for Demodex Blepharitis is a Approved program (small_molecule) at Tarsus Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Tarsus Pharmaceuticals
Indication
Demodex Blepharitis
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials